Summit Therapeutics Seeks Partnership For Phase 3 Infection Candidate Development

• In an SEC filing, Summit Therapeutics Inc (NASDAQ: SMMT) said it would seek partners or divestiture of ridinilazole as the path forward for the clinical development of the asset.

• Ridinilazole is the company’s Phase 3 product candidate for Clostridioides difficile infection (C. diff. infection or CDI).

• As a result of this determination, the company will discontinue its only active study for ridinilazole, a pediatric clinical trial evaluating ridinilazole, for treating adolescent patients with CDI.

• Related: Summit Therapeutics Mulls Additional Trial For Its Once Failed Infection Candidate.

• As previously communicated, the company held a Type C meeting with the FDA, during which the FDA and Summit discussed a possible pathway to advance ridinilazole to achieve marketing authorization.

• This pathway would involve at least one additional registrational trial, for which Summit will seek a partner to perform.

• Further, the company plans to present the data associated with ridinilazole's Phase 3 clinical trial, Ri-CoDIFy, at IDWeek 2022 later this month.

• Price Action: SMMT shares are trading higher by 2.06% at $1.23 on the last check Tuesday.

See more from Benzinga

• Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients

• Pfizer In-Licenses Voyager Therapeutics' AAV Capsid For Rare Neurologic Disease Target

• Trump's Former Secretary Of State Tillerson Says Unaware That Indicted Ally Was Privy To 'Sensitive' Disc

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.